In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice

Kirsten M. Raehal, John J. Lowery, Castigliano Bhamidipati, Ryan M. Paolino, Jennifer R. Blair, Danxin Wang, Wolfgang Sadée, Edward J. Bilsky

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The μ-opioid receptor displays basal signaling activity, which seems to be enhanced by exposure to opioid agonists. This study assesses the in vivo pharmacology of the putative "neutral" antagonist 6β-naltrexol in comparison to other ligands with varying efficacy, such as naloxone, an inverse agonist in the opioid-dependent state. ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine, and 6β-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence. 6β-Naltrexol was roughly equipotent to naloxone and between 4.5- and 10-fold less potent than naltrexone in blocking morphine-induced antinociception and locomotor activity, showing that 6β-naltrexol enters the central nervous system. In contrast to naloxone and naltrexone, 6β-naltrexol precipitated only minimal withdrawal at high doses in an acute dependence model and was ∼77- and 30-fold less potent than naltrexone and naloxone, respectively, in precipitating withdrawal in a chronic dependence model, 6β-Naltrexol reduced the inverse agonist effects of naloxone in vitro and in vivo, as expected for a neutral antagonist. Therefore, the pharmacological effects of 6β-naltrexol differ markedly from those of naloxone and naltrexone in the opioid-dependent state. A reduction of withdrawal effects associated with neutral μ-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction.

Original languageEnglish (US)
Pages (from-to)1150-1162
Number of pages13
JournalJournal of Pharmacology and Experimental Therapeutics
Volume313
Issue number3
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Fingerprint

Naltrexone
Naloxone
Opioid Analgesics
Ligands
Morphine
Nalbuphine
Pharmacology
Inbred ICR Mouse
Narcotic Antagonists
Opioid Receptors
Locomotion
6 beta-hydroxynaltrexone
Central Nervous System

ASJC Scopus subject areas

  • Pharmacology

Cite this

In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. / Raehal, Kirsten M.; Lowery, John J.; Bhamidipati, Castigliano; Paolino, Ryan M.; Blair, Jennifer R.; Wang, Danxin; Sadée, Wolfgang; Bilsky, Edward J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No. 3, 01.06.2005, p. 1150-1162.

Research output: Contribution to journalArticle

Raehal, Kirsten M. ; Lowery, John J. ; Bhamidipati, Castigliano ; Paolino, Ryan M. ; Blair, Jennifer R. ; Wang, Danxin ; Sadée, Wolfgang ; Bilsky, Edward J. / In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. In: Journal of Pharmacology and Experimental Therapeutics. 2005 ; Vol. 313, No. 3. pp. 1150-1162.
@article{730bcefda2bc4c7287a70a77b07f207b,
title = "In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice",
abstract = "The μ-opioid receptor displays basal signaling activity, which seems to be enhanced by exposure to opioid agonists. This study assesses the in vivo pharmacology of the putative {"}neutral{"} antagonist 6β-naltrexol in comparison to other ligands with varying efficacy, such as naloxone, an inverse agonist in the opioid-dependent state. ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine, and 6β-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence. 6β-Naltrexol was roughly equipotent to naloxone and between 4.5- and 10-fold less potent than naltrexone in blocking morphine-induced antinociception and locomotor activity, showing that 6β-naltrexol enters the central nervous system. In contrast to naloxone and naltrexone, 6β-naltrexol precipitated only minimal withdrawal at high doses in an acute dependence model and was ∼77- and 30-fold less potent than naltrexone and naloxone, respectively, in precipitating withdrawal in a chronic dependence model, 6β-Naltrexol reduced the inverse agonist effects of naloxone in vitro and in vivo, as expected for a neutral antagonist. Therefore, the pharmacological effects of 6β-naltrexol differ markedly from those of naloxone and naltrexone in the opioid-dependent state. A reduction of withdrawal effects associated with neutral μ-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction.",
author = "Raehal, {Kirsten M.} and Lowery, {John J.} and Castigliano Bhamidipati and Paolino, {Ryan M.} and Blair, {Jennifer R.} and Danxin Wang and Wolfgang Sad{\'e}e and Bilsky, {Edward J.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1124/jpet.104.082966",
language = "English (US)",
volume = "313",
pages = "1150--1162",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice

AU - Raehal, Kirsten M.

AU - Lowery, John J.

AU - Bhamidipati, Castigliano

AU - Paolino, Ryan M.

AU - Blair, Jennifer R.

AU - Wang, Danxin

AU - Sadée, Wolfgang

AU - Bilsky, Edward J.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - The μ-opioid receptor displays basal signaling activity, which seems to be enhanced by exposure to opioid agonists. This study assesses the in vivo pharmacology of the putative "neutral" antagonist 6β-naltrexol in comparison to other ligands with varying efficacy, such as naloxone, an inverse agonist in the opioid-dependent state. ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine, and 6β-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence. 6β-Naltrexol was roughly equipotent to naloxone and between 4.5- and 10-fold less potent than naltrexone in blocking morphine-induced antinociception and locomotor activity, showing that 6β-naltrexol enters the central nervous system. In contrast to naloxone and naltrexone, 6β-naltrexol precipitated only minimal withdrawal at high doses in an acute dependence model and was ∼77- and 30-fold less potent than naltrexone and naloxone, respectively, in precipitating withdrawal in a chronic dependence model, 6β-Naltrexol reduced the inverse agonist effects of naloxone in vitro and in vivo, as expected for a neutral antagonist. Therefore, the pharmacological effects of 6β-naltrexol differ markedly from those of naloxone and naltrexone in the opioid-dependent state. A reduction of withdrawal effects associated with neutral μ-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction.

AB - The μ-opioid receptor displays basal signaling activity, which seems to be enhanced by exposure to opioid agonists. This study assesses the in vivo pharmacology of the putative "neutral" antagonist 6β-naltrexol in comparison to other ligands with varying efficacy, such as naloxone, an inverse agonist in the opioid-dependent state. ICR mice were used to generate full antagonist dose-response curves for naloxone, naltrexone, nalbuphine, and 6β-naltrexol in blocking acute antinociceptive effects of morphine and precipitating opioid withdrawal in models of physical dependence. 6β-Naltrexol was roughly equipotent to naloxone and between 4.5- and 10-fold less potent than naltrexone in blocking morphine-induced antinociception and locomotor activity, showing that 6β-naltrexol enters the central nervous system. In contrast to naloxone and naltrexone, 6β-naltrexol precipitated only minimal withdrawal at high doses in an acute dependence model and was ∼77- and 30-fold less potent than naltrexone and naloxone, respectively, in precipitating withdrawal in a chronic dependence model, 6β-Naltrexol reduced the inverse agonist effects of naloxone in vitro and in vivo, as expected for a neutral antagonist. Therefore, the pharmacological effects of 6β-naltrexol differ markedly from those of naloxone and naltrexone in the opioid-dependent state. A reduction of withdrawal effects associated with neutral μ-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction.

UR - http://www.scopus.com/inward/record.url?scp=19444361830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444361830&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.082966

DO - 10.1124/jpet.104.082966

M3 - Article

C2 - 15716384

AN - SCOPUS:19444361830

VL - 313

SP - 1150

EP - 1162

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -